![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 299, Issue 2, 558-566, November 2001
Departments of Physiology (H.G.-S., R.C.) and Pharmacology and
Experimental Therapeutics (E.F.R.P., E.X.A.), University of Maryland
School of Medicine, Baltimore, Maryland; and Departamento de
Farmacologia Básica e Clínica (E.X.A., N.G.C., Y.A.,
P.A.M.), Instituto de Ciências Biomédicas, and Departamento
de Fármacos (P.C.L., C.A.M.F., E.J.B.), Faculdade de
Farmácia, Centro de Ciências da Saúde, Universidade
Federal do Rio de Janeiro, Rio de Janeiro, Brazil
This study was designed to investigate the effects on single skeletal
muscle fibers of a novel thienylhydrazone, referred to as LASSBio-294,
which is a bioisoster of pyridazinone compounds that inhibit the cyclic
AMP-specific phosphodiesterase (PDE) 4. Twitch and fatigue were
analyzed in single skeletal muscle fibers isolated from either the
semitendinous or the tibialis anterior muscles dissected from the frog
Rana pipiens. LASSBio-294 (12.5-100 µM) increased
twitch tension, accelerated the maximal rate of tension decay during
relaxation, and had very little effect in the maximal rate of tension
development of muscle fibers directly stimulated at
30 Hz. The
positive inotropic effect of LASSBio-294 developed slowly, reaching its
maximum at 40 min and was inversely proportional to the frequency of
stimulation, becoming negligible at 60 and 90 Hz. The
concentration-response relationship for LASSBio-294-induced potentiation of twitch tension was bell-shaped, with maximal effect occurring at 25 µM. In addition, LASSBio-294 reduced development of
fatigue induced by tetanic stimulation of the muscle fibers and reduced
the time needed for 80% prefatigue tension recovery after fatigue had
developed to 50% of the maximal pretetanic force. These effects of
LASSBio-294 can be fully explained by stimulation of the sarcoplasmic
reticulum Ca2+ pump and could be ascribed to an
increase in cellular levels of cyclic AMP due to PDE inhibition. The
novel thienylhydrazone LASSBio-294 may be useful for treatment of
patients suffering from conditions in which muscle fatigue is a
debilitating symptom (e.g., chronic heart failure).